In evaluating the EMIT' system for vancomycin used in the Cobas BioT centrifugal analyzer, we found two potential problems, each of which may have important clinical ramifications. First, precision, though acceptable in concentrations up to 30 mg/L, was marginal in the range above 30 mg/L. Second, when EMIT values were compared with those by fluorescent polarization immunoassay (TDx), we found a good correlation but a significant proportional bias: [EMIT] = (0.877)[TDx] + 0.435 mg/L (r = 0.971). The proportional bias was much more pronounced in specimens with high creatinine values than in specimens with normal values for creatmine. It remains to be determined which method is more nearly accurate. This imprecision and proportional bias in specimens with increased creatinines lead us to conclude that the EMIT vancomycin system should be used with caution.
Vancomycin is a glycopeptide antibiotic used in the treatment of sepsis caused by methicillin-resistant staphylococci (1) (2) (3) (4) . In addition, vancomycin is used in patients who are allergic to penicillins and cephalosporins, and in infections that cannot be treated with other drugs (1, 4) . Because the incidence of such infections has increased, the use of vancomycin has increased concomitantly (5).
In infections due to susceptible organisms, therapeutic concentrations in serum (peak 30-40 mg/L) can be achieved with little risk of toxicity (1, 6) . However, because of significant inter-individual variations in vancomycin pharmacokinetics, therapeutic drug monitoring is important to ensure efficacy (3, (7) (8) (9) (10) (11) . Current methods of measuring vancomycin in serum include bioassay (12) , HPLC (13) , RIA (14) , and fluorescence polarization immunoassay (FPLA) (6) . Recently, a homogeneous enzyme immunoassay (EMrr) for vancomycin (15) was introduced.
In this study we evaluated in detail the performance of the EMiT assay and compared results with those from the widely used FPIA system. Figure 2C ), the proportional bias was significantly smaller (slope = 0.986, P <0.001). The proportional bias between EMIT and FPIA persisted when fresh (n = 84) and frozen (n = 27) specimens were analyzed independently. Stored calibration curve. We next studied the possibility of using a stored calibration curve for determination of vancomycin by EMIT. A computer program was written that simulated the Cobas Bio DENS software; its performance was verified by using it to calculate results for other EMIT methods with the same mathematical model. Rates obtained for the vancomycin calibrators on the first day were entered into the program to establish a "stored curve." The rates obtained for the calibrators and controls on subsequent days were entered into the program as unknowns, and the program calculated the corresponding vancomycin values in two different ways, with and without correction for the change in the enzyme activity of the zero calibrator. Based on 11 runs over 36 days, for each calibrator (except de-ionized water as follows: 6.0 mL for reagents A and B, 1.0 mL for calibrators, and 3.0 mL for controls. The reagents, calibrators, and controls were equilibrated at room temperature for at least an hour before use. The working buffer solution was prepared by mixing one part of EMIT buffer assay concentrate with nine parts of de-ionized water. Working Reagent A was prepared by mixing one part of reconstituted Reagent A with 11 parts of working buffer solution. Reagent B was used undiluted. All materials were stored at 4 #{176}C between uses.
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Calibration curve. The calibration curve is constructed by plotting the enzyme activity of each standard minus the enzyme activity of the zero standard ("delta rate") vs the concentration of the standards. The delta rates generated with the five non-zero vancomycin calibrators were obtained for 10 between-run determinations of vancomycin. As shown in Figure 1 and Table 2 , the change in delta rates decreases with increasing vancomycin concentration. Between the 30 and 50 mgfL calibrators, the imprecision in the response (delta rates) of the calibrators themselves (2 SD of approximately 10 niA/min) translates to imprecision in the dose of about 7.1 mg/L.
Preciswn.
Precision was determined with the controls supplied by the manufacturer.
The within-run CV was 7.2% for Level 1 (n = 20, E = 6.9, SD = 0.5) and 5.7% for Level 2 (n = 20, E = 40.3, SD = 2.3). The between-run CV was 8.5% for Level 1 (n = 29, i = 7.7, SD = 0.7) and 6.1% for Level 2 (n = 29, i = 38.1, SD = 2.3). Analytical recovery. Using serum supplemented with vancomycin provided by the manufacturer (nine sets, spanning the range 5 to 50 mg/L), we determined vancomycin in duplicate by both EMIT and FPIA. Expressed as a percentage of FPIA, the average EMIT recovery was 95%.
Interference. Hemoglobin, lipid, and bilirubin were added to three different pooled specimens of human serum, which were then assayed to assess the effects of these common interferents on the EMIT assay. To avoid matrix effects, the interferents (Figure 3) . However, the Levey-Jennings plots for the controls (Figure 4) indicate that the values from the stored curve without zero-correction were not as reproducible as either the values from the stored curve with zero-correction or the values obtained on running a new curve with each run. Thus it is valid to run the EMIT vancomycin assay for at least a month with use of a stored curve protocol with zero correction.
Discussion
Our evaluation of the EMIT assay for vancomycin on the Cobas Bio provides some interesting dilemmas. As reflected in the initial quality-control data collected, the EMIT assay exhibits good precision, similar to that of FPIA, HPLC, or RIA (16, 17) . Our comparison studies indicate that results for patients' specimens correlate well with those by the widely used TDx system. In addition, the EMIT assay can be run against a stored curve, thus minimizing costs. Nonetheless, we discovered two potentially important problems.
Despite the good precision reflected in the quality-control materials, the relative flatness of the standard curve between the 30 and 50 mgfL calibrators (Figure 1 ) prompted us to do a dilution experiment. We chose two patients' specimens, one of which approximated the Level 2 control material and the other of which slightly exceeded the highest calibrator. We assayed each specimen, undiluted and twofold diluted, in 20 separate runs. As noted in Table  3 , sample A had a mean value of 36.4 mgfL (undiluted) and 40.6 mgfL (diluted), and the precision associated with each of these values was comparable to that for the Level 2 control. In contrast, sample B had a mean value of 44.6 mg/L (undiluted) and 56.9 mg/L (diluted). Of most concern is the fact that sample B was not flagged as >50 mg/L in 14 of the 20 runs. Thus, a patient's specimen with a potentially toxic concentration (57 mg/L) was assayed 70% of the time as <50 mg/L. The therapeutic peak range of vancomycin is commonly cited as 30-40 mgfL and toxicity is associated with concentrations >40 mg/L (1, 4, 6, 10 ), so this limitation of the EMIT assay could lead to incorrect Fig. 3 . Calibrator stability
The Cobas Bio data-reduction method was appliedto the curve generated from the calibrators run on day 1 to obtain the results "with zero-correction' and"without zero-correction'. Rates for the samples are correctedby using the rateforthe zero-calibrator either run atthe sametime [with zero-correction (#{149})J or run on day 1 (withOutzero-correction (0) Table 2 ). To assess in more detail the assay's precision in this area, we assayed by EMrr a series of specimens with various vancomycin concentrations, specimens we prepared by supplementing drug-free, serum with a pharmaceutical preparation of vancomycin.
As shown in Table 4 , despite good precision of the commercial quality-control material, the precision of the supplemented specimens, though acceptable up to about 35 mg/L, became problematic at higher Obviously, if the proportion of specimens in this concentration range is large, this strategy could prove expensive and impractical.
Our second concern stems from the correlation studies.
Our comparison
of patients' results, despite the good correlation, indicates a significant proportional bias of about 12% between EMIT and FPIA. However, the recovery study with supplemented sets indicates that results by the two methods should be similar. When we subdivided our patients based on their creatinine values ( Figure 2B, C) , the bias was minimized in patients with normal renal function but was more pronounced in patients with compromised renal function. One possible explanation of these results is that the FPIA antibody, but not the EMIT antibody, crossreacts with a compound that accumulates in the serum of patients with renal insufficiency.
Such a suggestion is not without precedent. A recent report by Morse et al. (18) showed that FPIA can overestimate vancomycin concentrations in patients who are undergoing peritoneal dialysis by 13% to 53% compared with HPLC. These authors suggested that the overestimation by FPIA was caused by the accumulation of vancomycin degradation products that cross-reacted with the FPIA antibody. Interestingly, previous comparison studies between FPIA and HPLC showed good correlation but varying proportional bias, including negative bias (19) , no bias (16, 20) , and positive bias (6, 21, 22) .
Thus, the existence of the proportional bias between EMIT and F'PIA presents two questions: whether compounds are formed in vivo that cross-react with either antibody, and, if present, whether such compounds are pharmacologically active. If such compounds exist and are pharmacologically active, then FPIA values may well be appropriate.
Otherwise, at least in some subsets of patients where such cross-reacting, pharmacologically inactive compounds accumulate, EMIT values are probably more nearly accurate. Until these questions are definitively answered, it is important to keep them in mind, no matter which method one chooses to use.
